Does cholesterol lowering prevent stroke?

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 5, 1998, Pages 337-344

  Henry, R Y ^a   Kendall, M J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMAGING; META ANALYSIS; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CEREBROVASCULAR DISORDERS; DIAGNOSTIC IMAGING; HUMANS; HYPERCHOLESTEROLEMIA; META-ANALYSIS; MULTICENTER STUDIES; PRAVASTATIN; RISK FACTORS;

EID: 0031649578     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00178.x     Document Type: Review

References (30)

1. American Heart Association. (1996) Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, Texas: American Heart Association.
2. Pedersen TR, Kjekshus J, Pyorala K, et al. (1998) Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). American Journal of Cardiology, 81, 333-335.
3. Simon LA, et al. (1998) Risk factors for ischaemic stroke: Dubbo study of the elderly. Stroke 29, 1341-1346.
4. Bennet NE. (1994) Hypertension in the elderly. Lancet, 344, 347-349.
5. Delanty N, Vaughan CJ. (1997) Vascular effects of statins in stroke. Stroke, 28, 2315-2320.
6. Neaton JD, Blackburn H, Jacobs D, et al. (1992) Serum cholesterol level and mortality findings for men screened in Multiple Risk Factor Intervention Trial. Archives of Internal Medicine, 152, 1490-1500.
7. Reed D, Yano K, Kagan A. (1986) Lipids and lipoproteins as predictors of coronary heart disease, stroke and cancer in the Honolulu Heart Program. American Journal of Medicine, 80, 871-878.
8. Gotto AM. (1997) Statin therapy and reduced incidence of stroke. Archives of Internal Medicine, 157, 1283-1284.
9. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. (1989) Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the Multiple Risk Factor Intervention Trial. New England Journal of Medicine, 320, 904-910.
10. Scandinavian Simvastatin Survival Study Group. (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
11. Sacks F, Pfeffer M, Moye L, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine, 335, 1001-1009.
12. The Lipid Study Group. (1995) Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. American Journal of Cardiology, 76, 474-479.
13. Shepherd J, Cobbe SM, Ford I, et al. (1995) Prevention of coronary heart disease in men with hypercholesterolemia. New England Journal of Medicine, 333, 1301-1307.
14. Furberg CD, Adams HP, Applegate WB, et al. (1994) Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation, 90, 1679-1687.
15. Salomen R, Nyyssonen K, Prkkala E, et al. (1995) Kuopio Atherosclerosis Prevention Study (KAPS) A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation, 92, 1758-1764.
16. Crouse JRIII, Byington RP, Bond MG, et al. (1995) Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-11). American Journal of Cardiology, 75, 455-159.
17. Crouse JRIII, Byington RP, Hoen HM, Furberg CD. (1997) Reductase inhibitor monotherapy and stroke prevention. Archives of Internal Medicine, 157, 1305-1310.
18. The Pravastatin Multinational Study Croup for Cardiac Risk Patients. (1993) Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/L (200-300mg/dl) plus two additional atherosclerotic risk factors. American Journal of Cardiology, 72, 1031-1037.
19. Pitt B, Mancini GBC, Ellis SG, Rosman HS, Park J-S, McGovern ME. (1995) Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC1): reduction in atherosclerosis progression and clinical events. Journal of the American College of Cardiology, 26, 1133-1139.
20. Jukema JW, Brushke AVG, van Boven AJ, et al. (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation, 91, 2528-2540.
21. Blakenhorn DH, Azen SP, Kramsch DM, Mars Research Group. (1993) Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Annals of Internal Medicine, 119, 969-976.
22. Waters D, Higginson L, Gladstone P, CAAIT Study Group. (1994) Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation, 89, 959-968.
23. Mercuri M, Bond MG, Sirtori C, et al. (1996) Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine, 101, 627-634.
24. Blauw GJ, Lagaay M, Smelt AHM, Westendorp RGJ. (1997) Stroke, statins and cholesterol: a Meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke, 28, 946-950.
25. Herbert PR, Gaziano JM, Chan KS, Hennekens CH. (1997) Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. Journal of the American Medical Association, 278, 313-321.
26. Bucher HC, Griffith LE, Guyatt GH. (1998) Effect of MHG-CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Annals of Internal Medicine, 128, 89-95.
27. Rosendorff C. (1998) Statins for the prevention of stroke. Lancet, 351, 1001-1003.
28. Vaughan CJ, Murphy MB, Buckley BM. (1996) Statins do more than just lower cholesterol. Lancet, 348, 1079-1082.
29. Kendall MJ. (1995) Treatment of the elderly hypertensive. In: Kendall MJ, Kaplan NM, Horton RC, eds. Difficult Hypertension: Practical Management and Decision Making, London: Martin Dunitz,
30. Spence JD. (1998) Statins for the prevention of stroke. Lancet, 352, 909.